Park K - Search Results

1

Target specific hyaluronic acid-interferon alpha conjugate for the treatment of hepatitis C virus infection.

Yang JA, Park K, Jung H, Kim H, Hong SW, Yoon SK, Hahn SK. Yang JA, et al. Among authors: park k. Biomaterials. 2011 Nov;32(33):8722-9. doi: 10.1016/j.biomaterials.2011.07.088. Epub 2011 Aug 26. Biomaterials. 2011. PMID: 21872329

2

Effect of hyaluronic acid molecular weight on the morphology of quantum dot-hyaluronic acid conjugates.

Kim J, Park K, Hahn SK. Kim J, et al. Among authors: park k. Int J Biol Macromol. 2008 Jan 1;42(1):41-5. doi: 10.1016/j.ijbiomac.2007.09.002. Epub 2007 Sep 11. Int J Biol Macromol. 2008. PMID: 17936350

3

Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis.

Jiang G, Park K, Kim J, Kim KS, Hahn SK. Jiang G, et al. Among authors: park k. Mol Pharm. 2009 May-Jun;6(3):727-37. doi: 10.1021/mp800176t. Mol Pharm. 2009. PMID: 19178144

4

Synthesis, characterization, and preliminary assessment of anti-Flt1 peptide-hyaluronate conjugate for the treatment of corneal neovascularization.

Oh EJ, Park K, Choi JS, Joo CK, Hahn SK. Oh EJ, et al. Among authors: park k. Biomaterials. 2009 Oct;30(30):6026-34. doi: 10.1016/j.biomaterials.2009.07.024. Epub 2009 Jul 31. Biomaterials. 2009. PMID: 19647313

5

Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives.

Oh EJ, Park K, Kim KS, Kim J, Yang JA, Kong JH, Lee MY, Hoffman AS, Hahn SK. Oh EJ, et al. Among authors: park k. J Control Release. 2010 Jan 4;141(1):2-12. doi: 10.1016/j.jconrel.2009.09.010. Epub 2009 Sep 13. J Control Release. 2010. PMID: 19758573 Review.

6

Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate.

Park K, Lee MY, Kim KS, Hahn SK. Park K, et al. Biomaterials. 2010 Jul;31(19):5258-65. doi: 10.1016/j.biomaterials.2010.03.018. Epub 2010 Apr 7. Biomaterials. 2010. PMID: 20378167

7

Target specific systemic delivery of TGF-β siRNA/(PEI-SS)-g-HA complex for the treatment of liver cirrhosis.

Park K, Hong SW, Hur W, Lee MY, Yang JA, Kim SW, Yoon SK, Hahn SK. Park K, et al. Biomaterials. 2011 Jul;32(21):4951-8. doi: 10.1016/j.biomaterials.2011.03.044. Epub 2011 Apr 11. Biomaterials. 2011. PMID: 21481451

8

Theranostic systems assembled in situ on demand by host-guest chemistry.

Jung H, Park KM, Yang JA, Oh EJ, Lee DW, Park K, Ryu SH, Hahn SK, Kim K. Jung H, et al. Among authors: park k, park km. Biomaterials. 2011 Oct;32(30):7687-94. doi: 10.1016/j.biomaterials.2011.06.060. Epub 2011 Jul 23. Biomaterials. 2011. PMID: 21788071

9

Cationic solid lipid nanoparticles derived from apolipoprotein-free LDLs for target specific systemic treatment of liver fibrosis.

Kong WH, Park K, Lee MY, Lee H, Sung DK, Hahn SK. Kong WH, et al. Among authors: park k. Biomaterials. 2013 Jan;34(2):542-51. doi: 10.1016/j.biomaterials.2012.09.067. Epub 2012 Oct 22. Biomaterials. 2013. PMID: 23092863

10

Reducible hyaluronic acid-siRNA conjugate for target specific gene silencing.

Park K, Yang JA, Lee MY, Lee H, Hahn SK. Park K, et al. Bioconjug Chem. 2013 Jul 17;24(7):1201-9. doi: 10.1021/bc4001257. Epub 2013 Jun 17. Bioconjug Chem. 2013. PMID: 23731084

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24,540 results

Search Page

Filters